Hepatic inflammatory biomarkers and its link with obesity and chronic diseases;Biomarcadores Hepáticos de inflamación y su vínculo con la obesidad y las enfermedades crónicas

Nutricion Hospitalaria

Volumn 31, Issue 5, 2015, Pages 1947-1956

  Volp, Ana Carolina Pinheiro ^a   Silva, Fernanda Cacilda Santos ^a   Bressan, Josefina ^b  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

Author keywords

Cardiovascular diseases; Diabetes; Inflammation; Insulin resistance; Obesity

Indexed keywords

BIOLOGICAL MARKER;

CHRONIC DISEASE; COMPLICATION; HEPATITIS; HUMAN; INSULIN RESISTANCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

BIOMARKERS; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HEPATITIS; HUMANS; INSULIN RESISTANCE; OBESITY;

EID: 84928813233     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2015.31.5.8525     Document Type: Article

References (59)

1. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004; 109: 2-10.
2. Wu JT, Wu LL. Linking inflammation and atherogenesis: Soluble markers identified for the detection of risk factors and for early risk assessment. Clin Chim Acta. 2006; 366: 74-80.
3. Zulet Ma A., Puchau B, Navarro C, Marti A, Martinez JA. Biomarcadores del estado inflamatorio: nexo de union con la obesidad y complicaciones asociadas. Nutr Hosp. 2007; 22(5): 511-27.
4. Volp ACP, Alfenas RCG, Costa NMB, Minim VPR, Stringueta PC, Bressan J. Capacidade dos biomarcadores inflamatorios em predizer a sindrome metabolica. Arq Bras Endocrinol Metabol. 2008; 52(3): 537-49.
5. Engstrom G, Stavenow L, Hedblad B, Lind P, Tyden P, Janzon L, et al. Inflammation sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. Arterioscler Thromb Vasc Biol. 2003; 23: 2247-51.
6. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson K-F, Janzon L, et al. Inflammation sensitive plasma proteins, diabetes, and incidence of myocardial infarction and stroke. Diabetes. 2003; 52: 442-7.
7. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): A cohort study. Lancet. 1999; 353: 1649-52.
8. Festa A, D’Agostino R, Tracy RP, Haffner S. Insulin resistance atherosclerosis study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes. 2002; 51: 1131-7.
9. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002; 105: 2632-7.
10. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol. 2005; 25: 989-94.
11. Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Letters 2008; 582: 97-105.
12. Engstrom G, Hedblad B, Stavenow L, Jonsson S, Lind P, Janzon L, et al. Incidence of obesity- associated cardiovascular disease is related to inflammation- sensitive plasma proteins: A population based cohort study. Arterioscler Thromb Vasc Biol. 2004; 24:1498-502.
13. Kannel WB, Wilson PW, Nam BH, D`Agostino RB. Risk stratification of obesity as a coronary risk factor. Am J Cardiol. 2002; 90: 697-701.
14. Jonsson S, Hedblad B, Engstrom G, Nilsson P, Berglund G, Janzon L. Influence of obesity on cardiovascular risk. Twentythree- year follow-up of 22,025 men from an urban Swedish population. Int J Obes Relat Metab Disord. 2002; 26: 1046-53.
15. Darvall KAL, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007; 33: 223-33.
16. Lindberg G, Rastam L, Gullberg B, Lundblad A, Nilsson-Ehle P, Hanson BS. Serum concentration of total sialic acid and sialoglycoproteins in relation to coronary heart disease risk markers. Atherosclerosis. 1993; 103: 123-9.
17. Rajappa M, Ikkruthi S, Nandeesha H, Satheesh S, Sundar I, Ananthanarayanan PH., et al. Relationship of raised serum total and protein bound sialic acid levels with hyperinsulinemis and indices of insulin sensitivity and insulin resistance in non-diabetic normotensive obese subjects. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2013;7:17-9.
18. Browning L, Krebs JD, Jebb SA. Discrimination ratio analysis of inflammatory markers: implications for the study of inflammation in chronic disease. Metabolism. 2004; 53(7): 899-903.
19. Browning LM, Jebb SA, Mishra GD, Cooke JH, O’Connell MA, Crook MA, et al. Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. Int J Obes. 2004; 28: 1004-10.
20. Crook MA, Miell J, Ameerally P, Lumb, P, Singh N, Russell- Jones D, et al. Serum sialic acid, a reputed cardiovascular risk factor, is related to serum leptin concentrations in Fijians. Clin Chim Acta. 2003; 331:1-5.
21. Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T. Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun. 2004; 321: 592-600.
22. Janciauskiene S, Moraga F, Lindgren S. C-terminal fragment of alpha1-antitrypsin activates human monocytes to a proinflammatory state through interactions with the CD36 scavenger receptor and LDL receptor. Atherosclerosis. 2001; 158: 41-51.
23. Moraga F, Janciauskiene S. Activation of primary human monocytes by the oxidized form of alpha1-antitrypsin. J Biol Chem. 2000; 275:7693-700.
24. Subramaniyam D, Glader P, Von Wachenfeldt K, Burneckiene J, Stevens T, Janciauskiene S. C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int J Biochem Cell Biol. 2006; 38: 563-75.
25. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Radic Biol Med. 2000; 28: 1735-44.
26. Uriu-Adams JY, Keen CL. Copper, oxidative stress, and human health. Mol Aspects Med. 2005; 26: 268-98.
27. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis. 2006;187: 238-50.
28. Giurgea N, Constantinescu MI, Stanciu R, Suciu S, Muresan A. Ceruloplasmin: Acute-phase reactant or endogenous antioxidant? The case of cardiovascular disease. Med Sci Monit. 2005; 11: 48-51.
29. Cignarelli M, Depergola G, Picca G, Sciaraffia M, Pannacciulli N, Tarallo M, et al. Relationship of obesity and body fat distribution with ceruloplasmin serum levels. Int J Obes Relat Metab Disord. 1996; 20:809-13.
30. Kim CH, Park JY, Kim JY, Choi CS, Kim YII, Chung YE, et al. Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: A population based study. Metabolism. 2002; 51: 838-42.
31. Exner M, Hermann M, Hofbauer R, Hartmann B, Kapiotis S, Gmeiner B. Homocysteine promotes the LDL oxidase activity of ceruloplasmin. FEBS Lett. 2002; 531: 402-6.
32. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol. 2001; 115:3-12.
33. Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42-7.
34. Celik A, Saricicek E, Saricicek V, Sahin E, Ozdemir G, Kiline M., et al. Relation between the new anthropometric obesity parameters amd inflammatory markers in healthy adult men. SCIRJ. 2014; 11(3): 6-10.
35. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, et al. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinical Sciences. 2006; 61(5): 433-40.
36. Ditschuneit HH, Flechtner-Mors M, Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res. 1995; 3:43-8.
37. Festa A, D’Agostino R, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999; 19: 562-68.
38. Simarro M, Carbayo JA, Artigao LM, Masso J, Divison JA, Ponce I., et al. Fibrinogen and mortality in a cohort population- based study. Exp Clin Cardiol. 2014; 20(5):3011-8.
39. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults: The ARIC Study. Obesity Research. 2000; 8(4): 279-86.
40. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev. 2002; 3: 85-101.
41. Fain JN, Bahouth SW, Madan AK. Haptoglobin release by human adipose tissue in primary culture. J Lipid Res. 2004; 45: 536-42.
42. Taes YE, De Bacquer D, De Backer G, Delanghe JR. Haptoglobin and body mass index. J Clin Endocrinol Metab. 2005; 90: 594.
43. Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 2005; 7: 729-36.
44. Chiellini C, Santini F, Marsili A, Berti P, Bertacca A, Pelosini C, et al. Serum haptoglobin: A novel marker of adiposity in humans. J Clin Endocrinol Metab. 2004; 89:2678-83.
45. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995; 346:1395-8.
46. Welch GN, Loscalzo J. Mechanisms of diseases: Homocysteine and atherothrombosis. N Engl J Med. 1998; 338: 1042-50.
47. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995; 274: 1049-57.
48. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996; 27:517-27.
49. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jakobs C, Bouter LM, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998; 18: 133-8.
50. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation. 2000; 101: 1506-11.
51. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med. 1999; 131: 363-75.
52. Sanchez-Margalet V, Valle M, Ruz FJ, Gascon F, Mateo J. Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects. J Nutr Biochem. 2002; 13(2): 75-9.
53. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997; 78(1): 656-60.
54. Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med. 1996; 2(5): 568-82.
55. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999; 19: 972-8.
56. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation. 2003; 107:398-404.
57. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolisis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000; 152: 897-907.
58. Volp ACP, Hermsdorff HHM, Bressan J. Glycemia and insulinemia evaluation after high-sucrose and high-fat diets in lean and overweight/obese women. J Physiol Biochem. 2008; 64(2):103-114.
59. Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184-223.